Get Support

Search global stocks & ETFs...Ctrl K

Learn Mode

PFE - Pfizer Inc

548

$26.45

$0.15 (0.570%)

At market close

$26.49

$0.04 (0.132%)

After Hours 5/5/26, 10:29 PM

3.28/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

PFE

Valuation Score

View as %

Stock Unlock

1D

1W

1M

YTD

1Y

3Y

5Y

Max

Stock Profile

Market Cap

$151.00B

Industry

Pharmaceuticals

EPS (TTM)

$1.36

P/E (TTM)

19.43

Div & Yield

$1.72 (6.50%)

FCF Payout Ratio

108.19%

P/S (TTM)

2.41

P/B

1.75

Diluted Shares

5.69B

Ex-Dividend

2026-05-08

Next Earnings

05-05

Forward P/E

9.08

Payout Ratio

126.37%

P/FCF (TTM)

16.64

FCF Yield

6.01%

Earnings Yield

5.15%

52 Week Range

Score Card

Explore Scores Tab

3.28

Average

Pfizer Inc has seen its revenue decline by -1.64% over the past year, which means the company is losing sales/customers. Also, it has a seen its free cash flow decrease by -7.72% over the past year, which suggests its profits are declining.

Valuation Model

Key Score

5.00

Very Good

Management

2.00

Bad

Growth

3.00

Average

Profitability

2.00

Bad

Fin. Health

3.00

Average

Dividends

4.00

Good

Analyst

2.00

Bad

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

2 new filings were in the last 7 days

Filter Form Types

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-04 16:20:12

Form SCHEDULE 13G

Unknown Form Type

Filed on 2026-05-01 08:39:25

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-27 18:40:00

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-27 18:39:59

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-27 18:39:58

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-27 18:37:58

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-27 18:37:57

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-27 18:37:56

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-27 18:37:54

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-27 18:23:32

Form 3/A

Unknown Form Type

Filed on 2026-04-27 18:23:31

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-27 18:22:31

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-04-25

High:

$37.80

42.9%

Avg:

$29.55

11.7%

Low:

$24.24

-8.4%

(% change is relative to the current stock price: $26.45)

Analyst Recommendations

Go to Analyst Tab

3.47

Good

14%

Strong Buy (5)

31%

Buy (11)

47%

Hold (17)

6%

Sell (2)

3%

Strong Sell (1)

About

Website
https://www.pfizer.com/
Address
66 Hudson Boulevard East, New York City NEW YORK, US
SEC Reports
https://sec.gov/edgar/browse/?CIK=78003

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The company is headquartered in New York City, New York and currently employs 75,000 full-time employees. The firm is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.

IPO Date

1944-01-17

Industry

Pharmaceuticals

Total Employees

75,000

Exchange

New York Stock Exchange, Inc.

Reporting Currency

USD

GICS

Pharmaceuticals

GICS Sub

Pharmaceuticals

GICS Sector

Health Care

GICS Group

Pharmaceuticals, Biotechnology & Life Sciences